Serum Activin A Level and 1‐Year Mortality in Atrial Septal Defect‐Associated Pulmonary Artery Hypertension: A Case‐Control Study From the COHARD‐PH Registry
International Journal of Vascular Medicine · 2026-01 · 2026 (1)
DOI: 10.1155/ijvm/7787559 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Vascular Medicine, online erschienen am 25.05.2026. Verfasst von Pranindya Rinastiti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Vascular Medicine, Faculty of Medicine, Public Health and Nursing Universitas Gadjah Mada-Dr. Sardjito Hospital, Yogyaka…. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitas Gadjah Mada.
Abstract (Originalsprache)
Background
Serum activin A level is a promising prognostic biomarker for pulmonary artery hypertension (PAH). In this study, we aim to investigate serum activin A levels and their associations with 1‐year mortality in atrial septal defect (ASD)–associated PAH patients.
Methods
This was a case‐control study of adult Indonesian patients diagnosed with ASD‐PAH from the COHARD‐PH registry. Cases were subjects deceased in a 1‐year follow‐up, whereas controls were those survived. Serum activin A was measured at the index of diagnosis. The demographics, clinical parameters, hemodynamic, and mortality data were retrieved from the registry database up to a 1‐year follow‐up period. These data were compared and analyzed between the case and control groups.
Results
From the 1‐year follow‐up data, 44 cases (deceased group) and 102 controls (survived group) were identified. The deceased group had significant lower bodyweight ( p < 0.001), body mass index (BMI) ( p < 0.01), with higher NT‐proBNP level (< 0.0001), higher proportion of Eisenmenger syndrome ( p < 0.05), higher right atrial (RA) area ( p < 0.0001), lower tricuspid annular plane systolic excursion (TAPSE) ( p < 0.01), and a significant increase in mean right atrial pressure (mRAP) (< 0.0001). There was no difference in the activin A level between deceased and survivors (506.3 ± 259.1 pg/mL vs. 536.1 ± 293.9 pg/mL, p > 0.05, respectively). Moreover, activin A level did not associate with the mortality risk among subjects (OR = 0.9996; 95% CI: 0.9982–1.00087; p > 0.05).
Conclusion
Serum activin A level did not associate with 1‐year mortality in adult patients with ASD‐associated PAH.
Autor:innen und Institutionen
- Department of Cardiology and Vascular Medicine, Faculty of Medicine, Public Health and Nursing Universitas Gadjah Mada-Dr. Sardjito Hospital, Yogyakarta, Indonesia, ugm.ac.id.
- Laboratory of Clinical Pharmaceutical Science, Kobe Pharmaceutical University, Kobe, Japan, kobepharma-u.ac.jp.
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, kobe-u.ac.jp.
ORCID-Profile: Pranindya Rinastiti, Anggoro Budi Hartopo, Cindy Elica Cipta, Dyah Wulan Anggrahini, Noriaki Emoto, Lucia Kris Dinarti
Förderung
- Universitas Gadjah Mada
Zitieren
APA
Rinastiti, P., Hartopo, A. B., Cipta, C. E., Maharani, S. G., Anggrahini, D. W., Emoto, N., & Dinarti, L. K. (2026). Serum Activin A Level and 1‐Year Mortality in Atrial Septal Defect‐Associated Pulmonary Artery Hypertension: A Case‐Control Study From the COHARD‐PH Registry. International Journal of Vascular Medicine, 2026(1). https://doi.org/10.1155/ijvm/7787559
Vancouver
Rinastiti P, Hartopo AB, Cipta CE, Maharani SG, Anggrahini DW, Emoto N, et al. Serum Activin A Level and 1‐Year Mortality in Atrial Septal Defect‐Associated Pulmonary Artery Hypertension: A Case‐Control Study From the COHARD‐PH Registry. International Journal of Vascular Medicine. 2026;2026(1). doi:10.1155/ijvm/7787559
BibTeX
@article{Rinastiti2026,
author = {Rinastiti, Pranindya and Hartopo, Anggoro Budi and Cipta, Cindy Elica and Maharani, Syallom Gita and Anggrahini, Dyah Wulan and Emoto, Noriaki and Dinarti, Lucia Kris},
title = {Serum Activin A Level and 1‐Year Mortality in Atrial Septal Defect‐Associated Pulmonary Artery Hypertension: A Case‐Control Study From the COHARD‐PH Registry},
journal = {International Journal of Vascular Medicine},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ijvm/7787559}
}
EUVIMED